SG11201907285XA - Methods and kits for generating mimetic innate immune cells from pluripotent stem cells - Google Patents
Methods and kits for generating mimetic innate immune cells from pluripotent stem cellsInfo
- Publication number
- SG11201907285XA SG11201907285XA SG11201907285XA SG11201907285XA SG11201907285XA SG 11201907285X A SG11201907285X A SG 11201907285XA SG 11201907285X A SG11201907285X A SG 11201907285XA SG 11201907285X A SG11201907285X A SG 11201907285XA SG 11201907285X A SG11201907285X A SG 11201907285XA
- Authority
- SG
- Singapore
- Prior art keywords
- cells
- mimetic
- international
- innate immune
- harvest
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title abstract 5
- 210000001778 pluripotent stem cell Anatomy 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 10
- 238000003306 harvesting Methods 0.000 abstract 5
- 210000004263 induced pluripotent stem cell Anatomy 0.000 abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 210000000822 natural killer cell Anatomy 0.000 abstract 3
- 239000007858 starting material Substances 0.000 abstract 3
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 2
- 241000549556 Nanos Species 0.000 abstract 2
- 230000002950 deficient Effects 0.000 abstract 2
- 230000004069 differentiation Effects 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 210000002536 stromal cell Anatomy 0.000 abstract 2
- 102100036462 Delta-like protein 1 Human genes 0.000 abstract 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 abstract 1
- 101000928537 Homo sapiens Delta-like protein 1 Proteins 0.000 abstract 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000002242 embryoid body Anatomy 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 210000000581 natural killer T-cell Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000004976 peripheral blood cell Anatomy 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/45—Artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
1 1-1 O GC N 1-1 00 1-1 O N C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT olimion °noI0 DIDmoIIVmoIIIII DIIIIII DID (10) International Publication Number WO 2018/147801 Al DO: Seed and culture hPSCs on OP9 cells (51) International Patent Classification: C12N 5/0783 (2010.01) A61K 35/17 (2015.01) C12N 5/10 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/SG2018/050051 (22) International Filing Date: 07 February 2018 (07.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201700937P 07 February 2017 (07.02.2017) SG 10201705582S 06 July 2017 (06.07.2017) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way #20-10 Connexis, Singapore 138632 (SG). (72) Inventors: ZENG, Jieming; c/o Institute of Bioengineer- ing and Nanotechnology, 31 Biopolis Way, The Nanos, #04-01, Singapore 138669 (SG). WANG, Shu; c/o Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, The Nanos, #04-01, Singapore 138669 (SG). (74) Agent: YUSARN AUDREY; 24 Raffles Place #27-01 Clif- ford Centre, Singapore 048621 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: METHODS AND KITS FOR GENERATING MIMETIC INNATE IMMUNE CELLS FROM PLURIPOTENT STEM CELLS Figure 1 a Hematepoietic Differentiation OP9 cells e-EVLEM + 20%FBS Lyn', I, it triti Commitment OP9-tLL1 cells s-NIENI + 20 F BS + Cytokntes 1 012: Harvest LH 9: Harvest D20: Harvest D33: Harvest 040 or D47: differentiated cells differentated cells differentiated cells differentiated cells Harvest NK cells and culture on and Culture on and culture on and culture on OP9-OLL1 OP9-0LL1 OP9•01.1.1 OP9-DLL1 (57) : Human pluripotent stem cells (hPSCs), especially induced pluripotent stem cells (iPSCs) provide a promising starting material to produce mimetic innate immune cells such as natural killer (NK) cells and yS T-cells for cancer immunotherapy. To facil- itate consistent mass production, an overall manufacturing scheme to make mimetic innate immune cells from hPSCs was designed and demonstrated. Particularly, a robust protocol to differentiate hPSCs into NK cells or yS T-cells through sequential hematopoietic differentiation on stromal cell line deficient in expressing M-CSF and lymphoid commitment on stromal cell line deficient in expressing M-CSF ectopically expressing DLL1 without employing CD34+ cell enrichment and spin embryoid body formation is established. Using this two-stage protocol, the generation of functional mimetic NK cells and functional mimetic NKT-cells was demonstrated yS from hPSCs, including hESCs, peripheral blood cell-derived iPSCs (PBC-iPSCs), non-T cell-derived iPSCs or yS T cell-derived iPSCs and the use of these mimetic innate immune cells in killing cancer cells.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201700937P | 2017-02-07 | ||
SG10201705582S | 2017-07-06 | ||
PCT/SG2018/050051 WO2018147801A1 (en) | 2017-02-07 | 2018-02-07 | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907285XA true SG11201907285XA (en) | 2019-09-27 |
Family
ID=63107773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907285XA SG11201907285XA (en) | 2017-02-07 | 2018-02-07 | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
SG10202106515SA SG10202106515SA (en) | 2017-02-07 | 2018-02-07 | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202106515SA SG10202106515SA (en) | 2017-02-07 | 2018-02-07 | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
Country Status (7)
Country | Link |
---|---|
US (1) | US20190359940A1 (en) |
EP (1) | EP3580332A4 (en) |
JP (1) | JP7092281B2 (en) |
CN (1) | CN110691844B (en) |
MY (1) | MY202222A (en) |
SG (2) | SG11201907285XA (en) |
WO (1) | WO2018147801A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201907285XA (en) * | 2017-02-07 | 2019-09-27 | Agency Science Tech & Res | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
WO2019053272A1 (en) | 2017-09-15 | 2019-03-21 | King's College London | Compositions and methods for enhancing gamma delta t cells in the gut |
US20210130777A1 (en) * | 2018-07-13 | 2021-05-06 | Kyoto University | Method for producing gamma delta t cells |
CN109321531A (en) * | 2018-11-03 | 2019-02-12 | 上海中溢精准医疗科技有限公司 | A method of gamma delta T cells induction is immunized into multipotential stem cell in peripheral blood |
CN110272871B (en) * | 2019-05-16 | 2021-08-27 | 安徽瑞达健康产业有限公司 | Composition for stimulating and inducing expansion of mononuclear cells into gamma delta T cells and application thereof |
CN111235105B (en) * | 2020-03-06 | 2021-08-10 | 安徽中盛溯源生物科技有限公司 | Method for differentiating human pluripotent stem cells into natural killer cells and application |
JP2023530919A (en) * | 2020-06-17 | 2023-07-20 | ヤンセン バイオテツク,インコーポレーテツド | Materials and methods for production of pluripotent stem cells |
CN111849913B (en) * | 2020-07-31 | 2021-05-25 | 南京北恒生物科技有限公司 | Engineered immune cells and uses thereof |
CN112662627B (en) * | 2021-01-19 | 2022-09-02 | 上海爱萨尔生物科技有限公司 | Culture solution for differentiating pluripotent stem cells into natural killer cells and differentiation method |
CN113440606A (en) * | 2021-06-02 | 2021-09-28 | 深圳市罗湖区人民医院 | Specific pluripotent stem cell tumor vaccine and preparation method and application thereof |
CN115261318B (en) * | 2021-09-29 | 2024-05-28 | 苏州艾凯利元生物科技有限公司 | Method for producing natural killer cells |
WO2023053994A1 (en) * | 2021-09-29 | 2023-04-06 | アイ ピース, インコーポレイテッド | Method for producing stem cells |
KR20230105166A (en) * | 2022-01-03 | 2023-07-11 | 주식회사 이뮤노맥스 | Method for Expansion Culture of γδ T Cell |
CN116042527B (en) * | 2022-09-07 | 2023-08-22 | 广州瑞臻再生医学科技有限公司 | iPS cell line for promoting NK cell differentiation and construction method and application thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003111595A (en) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | Tumor antigen |
BRPI0408774A (en) * | 2003-03-24 | 2006-03-28 | Scripps Research Inst | dna vaccines against tumor growth and their uses |
JPWO2006006720A1 (en) * | 2004-07-13 | 2008-05-01 | 株式会社メディネット | γδT cell culture method, γδT cell and therapeutic / prophylactic agent |
JP4281071B1 (en) * | 2008-07-10 | 2009-06-17 | 学校法人兵庫医科大学 | Vγ9Vδ2 T cell proliferating agent, method for producing activated Vγ9Vδ2 T cells and use thereof |
EP2336303B1 (en) | 2008-09-08 | 2015-07-15 | Riken | NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM |
US8772028B2 (en) * | 2008-11-07 | 2014-07-08 | Sunnybrook Health Sciences Centre | CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of using |
KR101772860B1 (en) * | 2009-06-05 | 2017-08-30 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | Reprogramming T cells and hematopoietic cells |
US8518397B2 (en) * | 2009-08-14 | 2013-08-27 | Case Western Reserve University | Notch induced natural killer cell generation and therapeutic uses |
US9206394B2 (en) * | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
GB201013767D0 (en) * | 2010-08-17 | 2010-09-29 | Isis Innovation | Identification of ligands and their use |
EP2841563B1 (en) * | 2012-04-24 | 2019-06-12 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
JP6164746B2 (en) | 2012-05-22 | 2017-07-19 | 国立大学法人 東京大学 | Method for producing antigen-specific T cells |
CN107429230B (en) * | 2015-01-26 | 2021-11-12 | 菲特治疗公司 | Methods and compositions for inducing hematopoietic cell differentiation |
JP2018518181A (en) * | 2015-06-17 | 2018-07-12 | ザ ユーエービー リサーチ ファンデーション | CRISPR / Cas9 complex for introducing functional polypeptides into cells of the blood cell lineage |
CA3003152A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
CA3048996A1 (en) * | 2015-12-08 | 2017-06-15 | Regents Of The University Of Minnesota | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using |
WO2018143243A1 (en) * | 2017-02-03 | 2018-08-09 | 国立大学法人神戸大学 | Method for producing induced pluripotent stem cells |
SG11201907285XA (en) * | 2017-02-07 | 2019-09-27 | Agency Science Tech & Res | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
-
2018
- 2018-02-07 SG SG11201907285XA patent/SG11201907285XA/en unknown
- 2018-02-07 SG SG10202106515SA patent/SG10202106515SA/en unknown
- 2018-02-07 CN CN201880022790.XA patent/CN110691844B/en active Active
- 2018-02-07 WO PCT/SG2018/050051 patent/WO2018147801A1/en unknown
- 2018-02-07 JP JP2019542694A patent/JP7092281B2/en active Active
- 2018-02-07 US US16/484,349 patent/US20190359940A1/en active Pending
- 2018-02-07 EP EP18751284.3A patent/EP3580332A4/en active Pending
- 2018-02-07 MY MYPI2019004546A patent/MY202222A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN110691844A (en) | 2020-01-14 |
MY202222A (en) | 2024-04-17 |
CN110691844B (en) | 2023-09-08 |
EP3580332A1 (en) | 2019-12-18 |
US20190359940A1 (en) | 2019-11-28 |
JP2020506713A (en) | 2020-03-05 |
WO2018147801A1 (en) | 2018-08-16 |
SG10202106515SA (en) | 2021-07-29 |
EP3580332A4 (en) | 2020-11-25 |
JP7092281B2 (en) | 2022-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907285XA (en) | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells | |
SG11201806988UA (en) | Improved differentiation method | |
SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
SG11201811405QA (en) | Improved differentiation method | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201909331UA (en) | Antigen-specific immune effector cells | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201407175RA (en) | Enhanced affinity t cell receptors and methods for making the same | |
SG11201908492PA (en) | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201805186VA (en) | Compositions and methods for immune cell modulation in adoptive immunotherapies | |
SG11201907319QA (en) | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201806002SA (en) | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process | |
SG11201807868VA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
SG11201408405WA (en) | Engineered three-dimensional connective tissue constructs and methods of making the same | |
SG11201805229YA (en) | Means and methods for treating hbv | |
SG11201408297XA (en) | Porous graphene oxide materials | |
SG11201407837WA (en) | Beta-hairpin peptidomimetics | |
SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
SG11201804997XA (en) | Process for preparing non-cariogenic, sustained energy release juice | |
SG11201904535VA (en) | Prevention and treatment of bone and cartilage damage or disease | |
SG11201903032SA (en) | Methods and compositions related to nk cell and anti-pdl1 cancer therapies | |
SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
SG11201807114TA (en) | Colony forming medium and use thereof |